Who makes CXL-1020 Doses for Echo Cohort B?

CXL-1020 Doses for Echo Cohort B is developed by Bristol-Myers Squibb.

What development phase is CXL-1020 Doses for Echo Cohort B in?

CXL-1020 Doses for Echo Cohort B is in Phase 1.

Last reviewed 2026-04-19 · How we verify

CXL-1020 Doses for Echo Cohort B

Bristol-Myers Squibb · Phase 1 active Small molecule

At a glance

Generic name	CXL-1020 Doses for Echo Cohort B
Sponsor	Bristol-Myers Squibb
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CXL-1020 Doses for Echo Cohort B CI brief — competitive landscape report
CXL-1020 Doses for Echo Cohort B updates RSS · CI watch RSS
Bristol-Myers Squibb portfolio CI